Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Furazolidone

FDA-approved product (tablet, oral), marketed as Furoxone.

Registered studies
49
Lab records
2
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Furazolidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Furazolidone. Its therapeutic class is shown instead.

WHO therapeutic group
Other antiinfectives and antiseptics
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC G01AX06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA23.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis91.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 2 lab records
Open Furazolidone in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Furazolidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection

    NCT03565484 · start 2019-01-01

    Registered record
    Registry ID
    NCT03565484
    Conditions
    Helicobacter Pylori Infection
    Interventions
    susceptibility guided therapy; personal medication history guided therapy; salvage treatment for failed eradication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2020-06-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionsusceptibility guided therapy; personal medication history guided therapy; salvage treatment for failed eradication
    PhasePhase 4
    Registry statusUnknown

  • Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection

    NCT03658746 · start 2019-01-01

    Registered record
    Registry ID
    NCT03658746
    Conditions
    Helicobacter Pylori Infection
    Interventions
    two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline); one proton pump inhibitor, colloidal bismuth pectin; two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-01-01
    Completion
    2019-12-31
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventiontwo sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline); one proton pump inhibitor, colloidal bismuth pectin; two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)
    PhasePhase 4
    Registry statusCompleted

  • A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

    NCT03658733 · start 2018-12-15

    Registered record
    Registry ID
    NCT03658733
    Conditions
    Helicobacter Pylori Infection
    Interventions
    esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days); rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-12-15
    Completion
    2019-10-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionesomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days); rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
    PhasePhase 4
    Registry statusUnknown

  • Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy

    NCT03609892 · start 2018-08-01

    Registered record
    Registry ID
    NCT03609892
    Conditions
    Gastric Ulcer; Chronic Gastritis; Gastric Cancer; Helicobacter Pylori Infection; Gastritis
    Interventions
    Berberine; Amoxicillin; Esomeprazole; Bismuth; Tetracycline; Furazolidone; Esomeprazole; Bismuth
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-08-01
    Completion
    2019-08-20
    Enrolment
    658

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Ulcer; Chronic Gastritis; Gastric Cancer; Helicobacter Pylori Infection +1 more
    InterventionBerberine; Amoxicillin; Esomeprazole; Bismuth +4 more
    PhasePhase 4
    Registry statusCompleted

  • A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication

    NCT03716622 · start 2018-07-31

    Registered record
    Registry ID
    NCT03716622
    Conditions
    Helicobacter Pylori
    Interventions
    Furazolidone; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-07-31
    Completion
    2019-08-31
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori
    InterventionFurazolidone; Clarithromycin
    PhasePhase 4
    Registry statusCompleted

  • Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.

    NCT03571230 · start 2018-07-01

    Registered record
    Registry ID
    NCT03571230
    Conditions
    Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    Interventions
    two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline); two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone); one proton pump inhibitor(PPI); Colloidal Bismuth Pectin; two antibiotics for failed eradication(tetracyclin,furazolidone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-07-01
    Completion
    2020-01-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    Interventiontwo sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline); two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone); one proton pump inhibitor(PPI); Colloidal Bismuth Pectin +1 more
    PhasePhase 4
    Registry statusUnknown

  • The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers

    NCT03342456 · start 2017-12-13

    Registered record
    Registry ID
    NCT03342456
    Conditions
    Duodenal Ulcer Due to Helicobacter Pylori
    Interventions
    Doxycycline Hyclate Enteric-Coated Capsules; Amoxicillin Capsules; Ilaprazole Enteric-Coated Tablets; Furazolidone Tablets; Potassium Citrate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-12-13
    Completion
    2019-09-20
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuodenal Ulcer Due to Helicobacter Pylori
    InterventionDoxycycline Hyclate Enteric-Coated Capsules; Amoxicillin Capsules; Ilaprazole Enteric-Coated Tablets; Furazolidone Tablets +1 more
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases

    NCT03320538 · start 2017-07-10

    Registered record
    Registry ID
    NCT03320538
    Conditions
    Peptic Ulcer Disease
    Interventions
    Hou Gu Mi Xi; Placebo; Rabeprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-07-10
    Completion
    2020-09-17
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeptic Ulcer Disease
    InterventionHou Gu Mi Xi; Placebo; Rabeprazole
    PhaseNot applicable
    Registry statusCompleted

  • Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

    NCT03139253 · start 2017-05-30

    Registered record
    Registry ID
    NCT03139253
    Conditions
    Antimicrobial Susceptibility Testing; Triple Therapy
    Interventions
    amoxicillin; clarithromycin; tinidazole; levofloxacin; furazolidone; tetracycline; Ilaprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-05-30
    Completion
    2017-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntimicrobial Susceptibility Testing; Triple Therapy
    Interventionamoxicillin; clarithromycin; tinidazole; levofloxacin +3 more
    PhasePhase 4
    Registry statusUnknown

  • Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

    NCT02988089 · start 2017-04-20

    Registered record
    Registry ID
    NCT02988089
    Conditions
    Helicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    Interventions
    Clarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone; amoxicillin and furazolidone or amoxicillin and tetracycline; amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-04-20
    Completion
    2017-09
    Enrolment
    480

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Antimicrobial Susceptibility Testing
    InterventionClarithromycin susceptibility dependant strategy; 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline ); proton pump inhibitor (PPI) and Colloidal Bismuth Pectin; amoxicillin and clarithromycin or amoxicillin and furazolidone +2 more
    PhasePhase 4
    Registry statusUnknown

  • Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection

    NCT02934048 · start 2016-10

    Registered record
    Registry ID
    NCT02934048
    Conditions
    Therapeutic Duration; Helicobacter Pylori; Antimicrobial Susceptibility Test; Eradication
    Interventions
    7-day triple regimen guided by AST; 10-day triple regimen guided by AST; 14-day triple regimen guided by AST
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-10
    Completion
    2017-06
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTherapeutic Duration; Helicobacter Pylori; Antimicrobial Susceptibility Test; Eradication
    Intervention7-day triple regimen guided by AST; 10-day triple regimen guided by AST; 14-day triple regimen guided by AST
    PhasePhase 4
    Registry statusUnknown

  • A Multi-center Study for Eradication of Refractory Helicobacter Pylori

    NCT02741414 · start 2016-06

    Registered record
    Registry ID
    NCT02741414
    Conditions
    Gastritis
    Interventions
    The result of H pylori culture based on gram staining and enzyme activity testing; The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole; The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2018-12
    Enrolment
    4,428

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastritis
    InterventionThe result of H pylori culture based on gram staining and enzyme activity testing; The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole; The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing
    PhaseNot applicable
    Registry statusUnknown

  • A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection

    NCT02689583 · start 2016-03

    Registered record
    Registry ID
    NCT02689583
    Conditions
    Gastritis; Gastric Ulcer
    Interventions
    Antibiotic selection based on the antibiotic susceptibility testing; PPI selection based on the CYP2C19 gene polymorphism; Probiotics usage based on the 16SrRNA sequencing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-03
    Completion
    Not recorded
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastritis; Gastric Ulcer
    InterventionAntibiotic selection based on the antibiotic susceptibility testing; PPI selection based on the CYP2C19 gene polymorphism; Probiotics usage based on the 16SrRNA sequencing
    PhaseNot applicable
    Registry statusUnknown

  • Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy

    NCT02894268 · start 2016-02

    Registered record
    Registry ID
    NCT02894268
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Doxycycline; Furazolidone; Esomeprazole; Colloidal Bismuth Subcitrate; Sensitivity antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-02
    Completion
    2019-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionDoxycycline; Furazolidone; Esomeprazole; Colloidal Bismuth Subcitrate +1 more
    PhasePhase 4
    Registry statusUnknown

  • Empirical Rescue Therapies of Helicobacter Pylori Infection

    NCT01668927 · start 2012-07

    Registered record
    Registry ID
    NCT01668927
    Conditions
    Functional Dyspepsia; Scarred Peptic Ulcer
    Interventions
    Proton Pump Inhibitor; Bismuth; Metronidazole; Tetracycline; Furazolidone; Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-10
    Enrolment
    424

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFunctional Dyspepsia; Scarred Peptic Ulcer
    InterventionProton Pump Inhibitor; Bismuth; Metronidazole; Tetracycline +2 more
    PhasePhase 4
    Registry statusCompleted